Date: 2011-10-12
Type of information: Development agreement
Compound: humanized anti-Clever-1 antibody FP-1304
Company: Faron Pharmaceuticals (Finland) Biovian (Finland)
Therapeutic area: Cancer - Oncology
Type agreement: development
manufacturing
production
Action mechanism: Clever-1 is Faron’s proprietary receptor target (e.g. EP patent 1463760) and the Clever-1 function-blocking antibodies are part of Faron’s expanding product pipeline. Both ex vivo and in vivo experimental work have demonstrated that blocking Clever-1 function with monoclonal
Disease:
Details: Faron Pharmaceuticals has contracted Biovian, Ltd. (Turku, Finland) to initiate the development of GMP manufacturing of Faron’s humanized anti-Clever-1 antibody FP-1304. This collaboration is aiming at the production of clinical grade FP-1304 for early phase I/II studies in the oncology area. Simultaneously with the manufacturing development, Faron will conduct more detailed studies on the expression of Clever-1 in various human tumors and their metastases, in an attempt to choose the most likely tumor type, which could benefit most from Clever-1 blocking. This work is mainly conducted by Faron’s scientific network.
Financial terms:
Latest news:
